Lawsuit alleges Inovio insiders hid manufacturing issues and overstated drug approval chances

A shareholder lawsuit claims Inovio Pharmaceuticals' executives misled investors by hiding problems with the manufacturing of their CELLECTRA device and overstating the likelihood of FDA approval for their INO-3107 drug. The suit alleges the company failed to disclose delays and insufficient data for accelerated FDA review, potentially impacting the drug's commercial prospects. Shareholders who bought stock before October 10, 2023, are encouraged to contact the law firm investigating the case. This legal action highlights risks for investors relying on company disclosures for drug development progress.